Overview

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

Status:
Terminated

Trial end date:
2019-02-25

Target enrollment:

Participant gender:

Summary

This is a phase Ⅱ, placebo-controlled, multicenter, dynamic randomized, double blind study of the efficacy and safety of RC18, a recombinant human B lymphocyte stimulating factor receptor-antibody fusion protein in subjects with inadequate response of TNF-α antagonists due to treat moderate and severe rheumatoid arthritis.

Phase:

Phase 2

Details

Lead Sponsor:

RemeGen
RemeGen Co., Ltd.

Treatments:

Antibodies
Methotrexate